Two other studies involving mRNA-2416 (a lipid nanoparticle-encapsulated mRNA encoding Human OX40L; NCT03323398) and mRNA-2752 (a lipid nanoparticle-encapsulated mRNA encoding Human OX40L, IL-23, and IL-36γ; NCT03739931) explored intratumoral injection of these vaccines alone or in combination with immune checkpoint blockade for patients with solid tumor malignancies or lymphoma 141. This evidence concerns the gene TNFSF4 and lymphoma.